Abstracts tagged "pain"

Abstract Number: 0721 • ACR Convergence 2023
Characterization of Numeric Rating Scales for Symptom Assessment in Polymyalgia Rheumatica
Tonya K Marmon¹, Jason C Cole², Claire Owen³, Sarah Mackie⁴ and David Katz⁵, ¹Marmon Biostatistics, Seattle, WA, ²P3 Research Consulting, Torrance, CA, ³Austin Health, Malvern East, Australia, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: Pain, stiffness, and fatigue have been defined as core assessment domains in polymyalgia rheumatica (PMR) by the OMERACT PMR Working Group (PMRWG). Patient partners…
Abstract Number: 1184 • ACR Convergence 2023
A Wearable-Sensor for Assessment of Gait and Chair Stand Patterns in People with Knee Osteoarthritis: Validation and Responsiveness to Treatment of a Potential Digital Biomarker
Deepak Kumar¹, Lukas Adamowicz², Benjamin Senderling¹, Mary Gheller¹, Michael LaValley³, Kathryn Bacon¹, Pirinka Georgiev², Charmaine Demanuele², Paul Wacnik² and Tuhina Neogi⁴, ¹Boston University, Boston, MA, ²Pfizer Inc., Cambridge, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose: The objectives of this study in people with knee osteoarthritis (OA) were to (a) examine the agreement between measures of gait and chair stand…
Abstract Number: 1595 • ACR Convergence 2023
Pharmacological Modulation of Krüppel-like Factor 4 Reduces the Severity of Experimental Osteoarthritis via Tissue Protection and Regeneration
Manabu Kawata¹, Merissa Olmer², Kristen Johnson³ and Martin K Lotz², ¹Scripps Research Institute, San Diego, CA, ²Scripps Research Institute, La Jolla, CA, ³CALIBR, La Jolla, CA
Background/Purpose: Krüppel-like factors (KLFs) are members of the zinc finger family of transcription factors, which includes 17 members in mammals. We found that expression of…
Abstract Number: 1836 • ACR Convergence 2023
Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium
Jennifer Rogers¹, Megan Clowse² and Amanda Eudy³, ¹Duke University, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University, Raleigh, NC
Background/Purpose: Patients with SLE experience distressing fibromyalgia-like symptoms of fatigue, widespread pain, mood disturbance, and brain fog that negatively impact quality of life and are…
Abstract Number: 2155 • ACR Convergence 2023
The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies
Peter C. Taylor¹, Arthur Kavanaugh², Peter Nash³, Janet Pope⁴, Georg Pongratz⁵, Bruno Fautrel⁶, Rieke Alten⁷, Ken Hasegawa⁸, Shangbang Rao⁹, Dick de Vries¹⁰, Pieter-Jan Stiers¹¹, Chris Watson¹² and René Westhovens¹³, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴University of Western Ontario, London, ON, Canada, ⁵Faculty of Medicine, Regensburg University, Regensburg, Germany, Regensburg, Germany, ⁶Sorbonne Université APHP, Paris, France, ⁷Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ⁸Global Medical Affairs Research, Gilead Sciences, Inc., Foster City, CA, ⁹Biostatistics, Gilead Sciences, Inc., Foster City, CA, ¹⁰Research and Development, Clinical Research, Galapagos BV, Leiden, Netherlands, ¹¹Biostatistics, Galapagos NV, Mechelen, Belgium, ¹²Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ¹³Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience substantial pain despite treatment, and consider pain control an important treatment outcome. This post hoc analysis…
Abstract Number: 0309 • ACR Convergence 2023
Efficacy, Safety, Pharmacokinetics and Immunogenicity of Repeated Dosing of GSK3858279 in Patients with Knee Osteoarthritis: A Phase I, Randomized, Double-Blind, Placebo-Controlled Study
Jagtar Singh Nijjar¹, Kathy Abbott-Banner², Riju Ray³, Sam Munoz Vicente¹, Jane H. Bentley¹, Catherine Muya¹, Sarah Siederer¹, Eirini Panoilia¹, Damon Bass⁴, Disala Fernando⁵ and Edward C. Emery¹, ¹GlaxoSmithKline, Stevenage, United Kingdom, ²GlaxoSmithKline, Brentford, United Kingdom, ³GSK Research, Triangle Park, ⁴GlaxoSmithKline, Upper Providence, RI, ⁵GlaxoSmithKline, Cambridge, United Kingdom
Background/Purpose: Chronic pain is an unmet need in osteoarthritis (OA) as current therapies have limited analgesia and side effects. The chemokine CCL17 mediates inflammatory pain…
Abstract Number: 0756 • ACR Convergence 2023
Validation of Quantitative Effusion-synovitis Volume Measured by Deep-learning: Data from the Osteoarthritis Initiative
Banafshe Felfeliyan¹, Stephanie Wichuk², Abhilash Hareendranathan³, Janet Ronsky⁴ and Jacob Jaremko², ¹University of Alberta, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Radiology and Diagnostic Imaging, Edmonton, AB, Canada, ⁴University of Calgary, Calgary, AB, Canada
Background/Purpose: Knee effusion-synovitis (ES) is an attractive target for therapeutic interventions in arthritis, since it is associated with stiffness, pain, and disease progression to arthroplasty.…
Abstract Number: 1189 • ACR Convergence 2023
Evaluating Neuropathic and Nociplastic Pain in Patients with Hip and Knee Osteoarthritis
Carly Conran¹, Larry Moreland², Andrew Clauw¹, Jennifer Seifert¹, Carson Keeter³, Craig Hogan¹ and Michael Dayton¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Denver, CO, ³University of Colorado, Aurora, CO

Background/Purpose: Chronic pain in patients with hip and knee osteoarthritis (OA) has been classically attributed to nociceptive pain pathways. Emerging evidence has demonstrated influence from…
Abstract Number: 1609 • ACR Convergence 2023
Associations Between SARS-Cov-2 Infection and Neuropathic Pain in Fibromyalgia Patients: A Cohort Study
Danilo Perretta¹, Daniele Mauro¹, flavia riccio¹, valentina marino¹, emma scoppetta², Francesco ciccia¹ and rosella tirri¹, ¹University of Campania - Luigi Vanvitelli, Naples, Italy, ²University of Salerno, Salerno, Italy
Background/Purpose: SARS-CoV-2 infection has been increasingly recognized for its potential neurological manifestations. Fibromyalgia (FM) patients, who already experience neuropathic pain, may be particularly vulnerable to…
Abstract Number: 1839 • ACR Convergence 2023
Value of Small Fiber Neuropathy in Fibromyalgia Patients in a Rheumatological Setting
Styliani Tsiami¹, Elena Enax-Krumova², Dietrich Sturm³, Matthias Vorgerd², Bjoern Buehring⁴, Juergen Braun⁵ and Xenofon Baraliakos¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Neurologische Klinik Universitätsklinikum Bergmannsheil Bochum, Ruhr-University Bochum, Bochum, Germany, ³Agaplesion Bethesda - Krankenhaus, Wuppertal, Klinik für Neurologie, Wuppertal, Germany, ⁴Krankenhaus St. Josef, Wuppertal, Klinik für Internistische Rheumatologie, Wuppertal, Germany, ⁵Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Small fiber neuropathy (SFN), a polyneuropathy (PNP) affecting A-delta and C-fibers has been described in patients with fibromyalgia (FM). Different patterns of small fiber…
Abstract Number: 2157 • ACR Convergence 2023
Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis
Maxime Dougados¹, Peter C. Taylor², David Gruben³ and Meriem Kessouri⁴, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Pfizer Inc., Groton, CT, ⁴Pfizer Inc., Paris, France
Background/Purpose: Pain is the most common symptom reported by patients (pts) with rheumatic disorders, such as RA.1 Improvement in pain with antirheumatic drugs is generally…
Abstract Number: 0313 • ACR Convergence 2023
The Influence of Pain Catastrophizing on Pain and Function After Knee Arthroplasty for Osteoarthritis
Diana, Xin Hui Chan¹, Seyed Ehsan Saffari², Steven, Bak Siew Wong³, Seng Jin Yeo¹, Vikki Wylde⁴, Julian Thumboo¹ and Ying Ying Leung¹, ¹Singapore General Hospital, Singapore, Singapore, ²Center for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore, ³Sengkang General Hospital, Singapore, Singapore, ⁴University of Bristol, Bristol, United Kingdom
Background/Purpose: To evaluate the association between pre-operative pain catastrophizing and pain and function outcomes up to one year after knee arthroplasty. Methods: We used data…
Abstract Number: 0817 • ACR Convergence 2023
Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial)
Bedru Abafita¹, Ambrish Singh¹, Dawn Aitken¹, Steffany Moonaz², Andrew J Palmer¹, Leigh Blizzard¹, Changhai Ding¹, Stan Drummen¹, Graeme Jones³, Kim Bennell⁴ and Benny Samuel Antony¹, ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Department of Clinical and Health Services Research, Southern California University of Health Sciences, Whittier, CA, ³Menzies Institute for Medical Research, University of Tasmania, Melbourne, Australia, ⁴University of Melbourne, Melbourne, Australia
Background/Purpose: There is uncertainty about the best type of exercise to optimise outcomes for people with knee osteoarthritis (OA). Strengthening exercise is commonly recommended. However,…
Abstract Number: 1191 • ACR Convergence 2023
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Ascending-Dose Study Evaluating the Safety, Tolerability and Pharmacokinetics of XG004 Applied Topically in Participants with Osteoarthritis of the Knee
Guang-Liang Jiang¹ and Feng Xu², ¹Xgene Pharmaceutical Inc., Lexington, MA, ²Xgene Pharmaceutical Inc., Altos Hills, CA
Background/Purpose: Globally osteoarthritis affects about 302 million patients, knee osteoarthritis accounts for 263 million and ranks the highest in disability and pain compared to OA…
Abstract Number: 1610 • ACR Convergence 2023
Digital Acceptance and Commitment Therapy Improves Fibromyalgia Outcomes: Results from a Pivotal, Multi-center, Randomized Controlled Trial
Michael Gendreau¹, Andrea Chadwick², Lance McCracken³, David Williams⁴, Daniel Clauw⁵, Juan Luciano⁶, Yifei Dai⁷, Nicolette Vega⁸, Zunera Ghalib⁸, Kristen Guthrie⁸, Allison Kraus⁸, Michael Rosenbluth⁸, Jennifer Zomnir⁹, Dana Reddy¹⁰ and Lesley arnold¹¹, ¹Gendreau Consulting, LLC, Poway, CA, ²Department of Anesthesiology, Pain, and Perioperative Medicine, University of Kansas School of Medicine, Kansas City, KS, ³Department of Psychology, Uppsala University, Uppsala, Sweden, ⁴Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁵Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁶Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona, Barcelona, Spain, ⁷Swing Therapeutics, Gainesville, FL, ⁸Swing Therapeutics, San Francisco, CA, ⁹DelRicht Resesarch, Mckinney, TX, ¹⁰Curavit, Scarsdale, NY, ¹¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH
Background/Purpose: Acceptance and Commitment Therapy (ACT), a form of guideline-recommended Cognitive Behavioral Therapy (CBT), has been empirically validated as a non-drug treatment for fibromyalgia (FM).…

« Previous Page
1
…
7
8
9
10
11
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].